Richtig G, Wolf M, Schulter G, et al. Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab. SMR 2017, P01-15.
Nivolumab plus ipilimumab versus sunitinib bij gevorderd RCC: extended follow-up CheckMate 214
okt 2019 | Uro-oncologie